Inhibition of NO Synthesis Enhances Chronic Cardiovascular and Renal Actions of Leptin

Acute studies suggest that leptin has pressor and depressor actions, including stimulation of sympathetic activity as well as increased release of NO from the vascular endothelium. The goal of this study was to examine the role of NO in modulating the chronic blood pressure, heart rate, and renal responses to hyperleptinemia, comparable to that found in obesity-induced hypertension. Male Sprague-Dawley rats were implanted with arterial and venous catheters, and mean arterial pressure and heart rate were monitored continuously 24 h/d. After a 4-day control period, the rats were infused with isotonic saline vehicle (n=6) or NG-nitro-l-arginine methyl ester (L-NAME, 10 &mgr;g/kg per minute; n=9) to inhibit NO synthesis for 7 days. After 7 days of vehicle or L-NAME administration, leptin was infused intravenously for 7 days at a rate of 0.5 &mgr;g/kg per minute, followed by a leptin infusion at 1.0 &mgr;g/kg per minute for 7 days, along with vehicle or L-NAME. A 21-day infusion of L-NAME alone (n=6) served as a control for the L-NAME+leptin rats. Although the low dose of leptin alone did not significantly elevate arterial pressure, it raised the heart rate by 18±3 bpm. The higher leptin infusion rate raised arterial pressure from 96±3 to 104±3 mm Hg but did not increase the heart rate further. L-NAME+leptin increased arterial pressure by 40±6 mm Hg and heart rate by 79±19 bpm compared with pretreatment levels. In control L-NAME rats, mean arterial pressure increased by 31±4 mm Hg, whereas the heart rate was not altered significantly compared with pretreatment levels. Neither chronic leptin infusion alone nor L-NAME alone altered the glomerular filtration rate or renal plasma flow significantly, but L-NAME+leptin reduced glomerular filtration rate by 27±11% and renal plasma flow by 47±9%. These results indicate that impaired NO synthesis mildly enhances the chronic renal hemodynamic and hypertensive effects of leptin but markedly amplifies the tachycardia caused by hyperleptinemia.

[1]  S. Fitzgerald,et al.  Role of sympathetic nervous system and neuropeptides in obesity hypertension. , 2000, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[2]  K. Hosoda,et al.  Pathophysiological role of leptin in obesity-related hypertension. , 2000, The Journal of clinical investigation.

[3]  L. Fratta,et al.  Leptin induces direct vasodilation through distinct endothelial mechanisms. , 2000, Diabetes.

[4]  J. Noguchi,et al.  Effects of leptin on fasting-induced inhibition of neuronal nitric oxide synthase mRNA in the paraventricular and supraoptic nuclei of rats , 1999, Brain Research.

[5]  J. Morley,et al.  Leptin and neuropeptide Y (NPY) modulate nitric oxide synthase: further evidence for a role of nitric oxide in feeding , 1999, Peptides.

[6]  G. Frühbeck.  Pivotal role of nitric oxide in the control of blood pressure after leptin administration. , 1999, Diabetes.

[7]  A. Allegra,et al.  Effects of intracerebroventricular leptin administration on food intake, body weight gain and diencephalic nitric oxide synthase activity in the mouse , 1998, British journal of pharmacology.

[8]  R. Flower,et al.  Inhibitory effect of peptides derived from the N‐terminus of lipocortin 1 on arachidonic acid release and proliferation in the A549 cell line: identification of E‐Q‐E‐Y‐V as a crucial component , 1998, British journal of pharmacology.

[9]  J. Flier,et al.  Obesity and the Hypothalamus: Novel Peptides for New Pathways , 1998, Cell.

[10]  Huiqing Lu,et al.  Intracerebroventricular Leptin Increases Lumbar and Renal Sympathetic Nerve Activity and Blood Pressure in Normal Rats , 1997, Diabetes.

[11]  A. Mark,et al.  Sympathetic and cardiorenal actions of leptin. , 1997, Hypertension.

[12]  A. Mark,et al.  Receptor-mediated regional sympathetic nerve activation by leptin. , 1997, The Journal of clinical investigation.

[13]  E. Jackson,et al.  Human leptin has natriuretic activity in the rat. , 1997, The American journal of physiology.

[14]  R. Cone,et al.  Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice , 1997, Cell.

[15]  Victor J. Hruby,et al.  Role of melanocortinergic neurons in feeding and the agouti obesity syndrome , 1997, Nature.

[16]  R. Palmiter,et al.  Attenuation of the Obesity Syndrome of ob/ob Mice by the Loss of Neuropeptide Y , 1996, Science.

[17]  R. Considine,et al.  Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance , 1996, The Lancet.

[18]  J. Habener,et al.  Leptin receptors expressed on pancreatic beta-cells. , 1996, Biochemical and biophysical research communications.

[19]  Steven L. Cohen,et al.  Weight-reducing effects of the plasma protein encoded by the obese gene. , 1995, Science.

[20]  R. D. Manning,et al.  Nitric oxide regulates renal hemodynamics and urinary sodium excretion in dogs. , 1994, Hypertension.

[21]  B. Lowell,et al.  Development of obesity in transgenic mice after genetic ablation of brown adipose tissue , 1993, Nature.

[22]  D. Earle,et al.  Comparison of the constant infusion and urine collection techniques for the measurement of renal function. , 1948, The Journal of clinical investigation.

[23]  M. Brands,et al.  Chronic leptin infusion increases arterial pressure. , 1998, Hypertension.

[24]  A. De Luca,et al.  Electrical properties of diaphragm and EDL muscles during the life of dystrophic mice. , 1997, The American journal of physiology.

[25]  A C Guyton,et al.  Pressure-volume regulation in hypertension. , 1996, Kidney international. Supplement.